Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0VASWD |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | huCDCP1 (F30-T667 Q525)-8xHis_T3 |
|||||
| Synonyms |
huCDCP1 (F30-T667 Q525)-8xHis_T3
Click to Show/Hide
|
|||||
| Antigen Name | Undisclosed |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
aU2023308528A1 mAb-vcMMAE (DAR of 4) [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | < 5% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 1 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 20% | |||
| Method Description |
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 1 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 30% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||
aU2023308528A1 ADC4 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 20% | |||
| Method Description |
ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 10 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
|
||||
| In Vivo Model | MDA-MB-231 Xenograft Model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 6 mg/kg on day 1, dayv8 and day 15. time lasted 57 days.
|
||||
| In Vivo Model | MDA-MB-231 Xenograft Model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 80% | |||
| Method Description |
ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 10 mg/kg on day 1, dayv8 and day 15. time lasted 57 days.
|
||||
| In Vivo Model | MDA-MB-231 Xenograft Model | ||||
aU2023308528A1 ADC3 (DAR of 8) [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive CALU-6 expression (CALU-6+++/++) | ||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 10 mg/kg.
|
||||
| In Vivo Model | NSCLC CALU-6 (lung cancer) model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | |||
| Method Description |
ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 10 mg/kg.
|
||||
| In Vivo Model | MDA-MB-231 (TNBC) model | ||||